Page 2 - Gross Motor Function News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gross motor function. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gross Motor Function Today - Breaking & Trending Today

Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol for mitochondrial diseases

Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol for mitochondrial diseases
April 21, 2021 07:00 ET
| Source:
Khondrion
Khondrion
Study will examine
of sonlicromanol,
candidates in development
for mitochondrial disease
NIJMEGEN, the Netherlands – 21 April 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the first patients have been successfully dosed in its KHENERGYC paediatric Phase II study (NCT04846036) to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children with a genetically confirmed primary mitochondrial disease and suffering from motor symptoms.
Sonlicromanol, Khondrion’s wholly-owned, investigational lead asset, is currently being tested in a Phase IIb study as a potentially disease-modifying treatment for adults with mitochon ....

David Daley , Jan Smeitink , Melissa Gardiner , Mary Jane Elliott , Radboud Centre For Mitochondrial Medicine , Consilium Strategic Communications , Radboud Centre , Mitochondrial Medicine , Dutch Patient Foundations , Gross Motor Function , Nine Hole Peg , Chief Executive Officer , Orphan Drug Designations , Rare Pediatric Disease , Jane Elliott , டேவிட் டேலி , மெலிசா தோட்டக்காரர் , மேரி ஜேன் எலியட் , கொன்சில்ிும் மூலோபாய தகவல்தொடர்புகள் , மைட்டோகாண்ட்ரியல் மருந்து , தலைமை நிர்வாகி அதிகாரி , ரேர் குழந்தை நோய் , ஜேன் எலியட் ,

Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol .
KhondrionApril 21, 2021 GMT
Study will examine
of sonlicromanol,
candidates in development
for mitochondrial disease
NIJMEGEN, the Netherlands – 21 April 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the first patients have been successfully dosed in its KHENERGYC paediatric Phase II study ( NCT04846036 ) to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children with a genetically confirmed primary mitochondrial disease and suffering from motor symptoms.
ADVERTISEMENT ....

David Daley , Jan Smeitink , Melissa Gardiner , Mary Jane Elliott , Radboud Centre For Mitochondrial Medicine , Consilium Strategic Communications , Radboud Centre , Mitochondrial Medicine , Dutch Patient Foundations , Gross Motor Function , Nine Hole Peg , Chief Executive Officer , Orphan Drug Designations , Rare Pediatric Disease , Jane Elliott , டேவிட் டேலி , மெலிசா தோட்டக்காரர் , மேரி ஜேன் எலியட் , கொன்சில்ிும் மூலோபாய தகவல்தொடர்புகள் , மைட்டோகாண்ட்ரியல் மருந்து , தலைமை நிர்வாகி அதிகாரி , ரேர் குழந்தை நோய் , ஜேன் எலியட் ,